Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

MRK trims its 2025 sales range but lifts the lower end of its EPS outlook. Keytruda, Animal Health and new drugs are expected ...

IO Biotech's Phase 3 trial showed Cylembio plus Keytruda improved progression-free survival in advanced melanoma across most ...

IO Biotech said on Monday its experimental cancer vaccine, in combination with Merck's Keytruda, showed improvement in a late ...

IO Biotech said on Monday its experimental combination cancer vaccine helped slow the disease's progression in a late-stage ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

Shares of IO Biotech fell after the company said a cancer vaccine narrowly missed statistical significance on a Phase 3 study's primary endpoint. The stock was down 36%, to $1.15, late Monday ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

IO Biotech (IOBT) announced on Monday that its investigational and therapeutic cancer vaccine, Cylembio, in combination with ...

IO Biotech (NASDAQ:IOBT) stock gained 6.1% after revealing topline data from its pivotal Phase 3 trial evaluating Cylembio, ...

Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...